{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:54Z","timestamp":1793957214942,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107981","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:53:36Z","timestamp":1791672816000},"page":"107981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8386-2451","authenticated-orcid":false,"given":"Patrick","family":"Reardon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Fabis-Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vachova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbysek","family":"Pavelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Stourac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Stetkarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gross-Paju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Millan-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izanne","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Houskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Recmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Peterka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Ampapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor Brecl","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107981_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000204967","article-title":"OLIKOS Study: 6-month interim efficacy and safety in patients with relapsing multiple sclerosis who switched to subcutaneous Ofatumumab from intravenous anti- CD20 therapies","volume":"102","author":"Alvarez","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107981_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","article-title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice","volume":"15","author":"Amin","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2026.107981_bib0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107981_bib0004","first-page":"956","article-title":"Efficacy of early Ofatumumab versus late-switch from Teriflunomide: subgroup analysis of the ALITHIOS open-label extension study by prior disease modifying therapy exposure and age","volume":"28","author":"Cohen","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107981_bib0005","first-page":"1","article-title":"Efficacy of ofatumumab in treatment-naive, first-switch and late-switch patients: insights from the Alithios openlabelextension study","volume":"43","author":"Cohen","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107981_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104881","article-title":"Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic","volume":"78","author":"Coyle","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107981_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"De S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107981_bib0008","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107981_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107981_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107981_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206124","article-title":"Ofatumumab in different RMS patient populations in everyday clinical practice in Germany","volume":"102","author":"Nelles","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107981_bib0013","first-page":"1248","article-title":"Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States","volume":"30","author":"Qian","year":"2024","journal-title":"J. Manage Care Spec. Pharm."},{"key":"10.1016\/j.msard.2026.107981_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107981_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/13524585211005657","article-title":"Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy","volume":"28","author":"Signoriello","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107981_bib0016","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","article-title":"Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study","volume":"271","author":"Zangh\u00ec","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107981_bib0017","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/13524585211049986","article-title":"Prediction of multiple sclerosis outcomes when switching to ocrelizumab","volume":"28","author":"Zhong","year":"2022","journal-title":"Mult. Scler. J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826010163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826010163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:40:35Z","timestamp":1793954435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826010163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":16,"alternative-id":["S2211034826010163"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107981","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107981"}}